Handok took part in the 1^st DTx Asia, which is Asia’s first digital therapeutics conference, held at the Novotel Ambassador Hotel in Gangnam-gu, Seoul on November 8 and 9, 2022.

The 1st DTx Asia in Seoul is the 15th DTx Summit and the first such event held in Asia. DTx Summit is the world’s largest event related to digital therapeutics, and every year, DTx East and DTx West are held in the eastern and western United States while DTx Europe takes place in Europe. The 1st DTx Asia was attended by global pharmaceutical companies such as Novartis, Johnson & Johnson, Pair Therapeutics, Welt, Handok, and Cure App, as well as domestic digital therapeutics companies, pharmaceutical companies, and investors. The conference dealt with issues facing the present and future of the digital therapeutics industry in Asia.

Handok participated as Summit Partner and speaker. Handok Senior Managing Director and CEO of Handok’s subsidiary Innocube Kwon Sohyun participated in a joint session with Welt CEO Kang Sungjee on the afternoon of November 8 and gave a presentation on the partnership strategy between a digital therapeutics company and a pharmaceutical company. During the event, Handok exchanged information with various companies related to digital medicine.

As part of an ongoing open innovation initiative, Handok entered into a strategic partnership with Welt in 2021, expanding its R&D scope to digital therapeutics as well as new biologics and medical devices. Through this, it is participating in Welt’s ongoing development of digital treatments for alcoholism and insomnia, strengthening capabilities in research, development and commercialization of digital treatments. Of these efforts, the partnership’s digital treatment for insomnia received approval for a confirmatory clinical trial from the Korean Ministry of Food and Drug Safety in September last year and is currently undergoing clinical trials.

Handok has exclusive sales rights in the domestic market for digital treatment of alcoholism and insomnia. Welt has priority review rights for domestic joint development and commercialization of digital therapeutics that are being developed or for which plans are underway for development. Going forward, Handok plans to secure competitiveness in the rapidly growing digital healthcare market, effectively develop and launch innovative digital treatments based on its lengthy experience, and become a research leader.